Residual platelet activity and clinical failure of antithrombotic prophylaxis in acute cerebral ischaemic stroke;Attività piastrinica residua e fallimento clinico della profilassi antitrombotica nell'attacco ischemico cerebrale acuto

Rivista Italiana della Medicina di Laboratorio

Volumn 7, Issue 3, 2011, Pages 163-169

  De Boni, Antonella ^a   De Riva, Valentina ^a   Galloni, Elisabetta ^a   Perini, Francesco ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

Author keywords

Aspirin resistance; Clopidogrel resistance; Light transmission aggregometry (LTA); Platelet aggregation; Residual platelet activity

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL;

ARTICLE; BRAIN ISCHEMIA; HUMAN; LIGHT TRANSMISSION AGGREGOMETRY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TREATMENT FAILURE;

EID: 80955148348     PISSN: 1825859X     EISSN: 20396821     Source Type: Journal    
DOI: 10.1007/s13631-011-0024-8     Document Type: Article

References (23)

1. Pugliano M, Cattaneo M (2009) Il problema della resistenza ai farmaci antipiastrini: meccanismo molecolare e test di laboratorio. RIMeL/IJLaM 5:119-124
2. Eikelboom JW, Jon Emery J, Hankey GJ (2010) The use of platelet function assays may help to determine appropriate antiplatelet treatment options in a patient with recurrent stroke on baby aspirin. Stroke 41:2398-2399
3. Gachet C (2008) P2 receptors, platelet function and pharmacological implications. Thromb Haemost 99:466-472 (Pubitemid 351549282)
4. Hulot JS, Bura A, Villard E et al (2006) Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108:2244-2247 (Pubitemid 44497506)
5. Brandt JT, Close SL, Iturria SJ et al (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 5:2429-2436 (Pubitemid 350154353)
6. Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P450 polymorphisms and the response to clopidogrel. N Engl J Med 360:354-362
7. Fontana P, Dupont A, Gandrille S at al (2003) Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108:989-995 (Pubitemid 37048230)
8. Giorgi MA, Di Girolamo G, González CD (2010) Nonresponders to clopidogrel: pharmacokinetics and interactions involved. Expert Opin Pharmacother 11:2391-2403
9. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2005) Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 115:101-108 (Pubitemid 39572762)
10. Alberts MJ (2010) Platelet function testing for aspirin resistance is reasonable to do. Yes! Stroke 41:2400-2401
11. Selim MH, Molina CA (2010) Platelet function assays in stroke management more study is needed. Stroke 41:2396-2397
12. Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ (2005) An evidence-based causative classification system for acute ischemic stroke. Ann Neurol 58:688-697 (Pubitemid 41552544)
13. Cattaneo M (2009) Light transmission aggregometry and ADP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 35:158-167
14. Gum PA, Kottke-Marchant K, Welsch PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961-965 (Pubitemid 36315537)
15. Bonello L, Tantry US, Marcucci R et al (2010) Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919-933
16. Mansour K, Taher AT, Musallam KM, Alam S (2009) Aspirin resistance. Adv Hematol doi: 10.1155/2009/937352
17. Chrissobolis S, Faraci FM (2008) The role of oxidative stress and NADPH oxidase in cerebrovascular disease. Trend Mol Med 14:495-502
18. Lovett JK, Coull AJ, Rothwell PM (2004) Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 62:569-573 (Pubitemid 38252797)
19. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246-251 (Pubitemid 40094733)
20. Hankey GJ, Werner H, Easton JD et al (2010) Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients. A prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Stroke 41:1679-1683
21. Norris JW, Barnett HJ (2006) CHARISMA: the antiplatelet saga continues. Stroke 37:2428-2429 (Pubitemid 44337194)
22. Bhatt DL, Fox KA, Hacke W et al (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354:1706-1717
23. Diener HC, Bogousslavsky J, Brass LM et al (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364:331-337